Capricor falls as FDA sets up AdCom meeting to review Duchenne therapy
Seeking Alpha ·
Capricor Therapeutics ( CAPR ) lost ~12% on Friday after the U.S. FDA scheduled an advisory committee meeting to discuss the company’s marketing application for Deramiocel, a treatment targeting Duchenne muscular dystrophy. According to a federal notice on Friday, the FDA’s Cellular, Tissue, and Gene
DYAX Investor Sentiment
Bullish (Long) 55% · Bearish (Short) 45%
418 participants
Related News
- Apple price hikes may not matter because of lock-in, financing, inelastic demand: MS
- Wells Fargo Flags Anthropic Coding Improvement
- Nvidia, Micron, AMD Lead Chip Selloff on OpenAI IPO Delay Report Rattles Tech
- Amazon Tests AI Compute Pricing Power
- Tobacco stocks edge higher as FDA proposes rule on foreign manufacturers
- Could the Cryptocurrency XRP Turn $1,000 Into $10,000?